DeepMed Research

Abramson Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.pennmedicine.org

Clinical Trials

A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma

Phase 1

Completed

Conditions: Melanoma

First Posted Date: 2013-07-11

Last Posted Date: 2020-05-29

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 8

Registration Number: NCT01897116

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Ovarian Tissue Transplantation

Not Applicable

Recruiting

Conditions: Infertile Females or Females With Ovarian Insufficiency

Interventions: Procedure: Transplantation of previously cryopreserved ovarian tissu

First Posted Date: 2013-06-06

Last Posted Date: 2024-08-22

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 10

Registration Number: NCT01870752

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma

Phase 2

Completed

Conditions: Pancreatic Adenocarcinoma

Interventions: Drug: FOLFIRINOX
Drug: Gemcitabine
Radiation: Chemoradiation
Drug: Abraxane

First Posted Date: 2013-04-25

Last Posted Date: 2021-02-25

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 32

Registration Number: NCT01839799

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

APBI Proton Feasibility and Phase II Study

Phase 1

Completed

Conditions: Stage IA-IIA Breast Cancer

Interventions: Radiation: Proton Therapy

First Posted Date: 2013-04-25

Last Posted Date: 2024-11-07

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 40

Registration Number: NCT01839838

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Proton Therapy for High Risk Prostate Cancer

Not Applicable

Withdrawn

Conditions: Prostate Cancer

Interventions: Radiation: Radiation therapy (XRT)
Other: Androgen Deprivation Therapy (ADT)
Other: Chemotherapy

First Posted Date: 2013-03-15

Last Posted Date: 2019-04-23

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Registration Number: NCT01811810

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Multiple Myeloma and Exercise

Not Applicable

Completed

Conditions: Newly Diagnosed Multiple Myeloma

Interventions: Other: Weight Lifting Exercises

First Posted Date: 2013-03-13

Last Posted Date: 2020-03-10

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 10

Registration Number: NCT01809717

Locations: 🇺🇸
Abramson Cancer Center of the Unviersity of Pennsylvania, Philadelphia, Pennsylvania, United States

Intraoperative Imaging of Breast Cancer With Indocyanine Green

Early Phase 1

Completed

Conditions: Invasive Lobular Carcinoma
Ductal Carcinoma
Invasive Ductal Carcinoma

Interventions: Drug: Indocyanine Green

First Posted Date: 2013-02-21

Last Posted Date: 2021-01-28

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 10

Registration Number: NCT01796041

Locations: 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Phase II Maraviroc for GVHD Prevention

Phase 2

Completed

Conditions: Hematologic Malignancy

Interventions: Drug: Maraviroc 300 mg

First Posted Date: 2013-02-07

Last Posted Date: 2021-01-11

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 37

Registration Number: NCT01785810

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Etirinotecan Pegol (NKTR-102) in NSCLC

Phase 2

Completed

Conditions: Metastatic Non Small Cell Lung Cancer
Recurrent Non Small Cell Lung Cancer

Interventions: Drug: Etirinotecan pegol (NKTR-102)

First Posted Date: 2013-01-23

Last Posted Date: 2020-04-03

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 40

Registration Number: NCT01773109

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

A Study of the Communication of Genetic Test Results By Telephone: A Multi-Center Study

Completed

Conditions: Candidates for BRCA 1/2 Genetic Testing

Interventions: Genetic: Genetic Providers
Other: Visual Aids
Other: Post-Disclosure Asessments
Other: In-person Clinical Follow-Up
Other: 6 Month and 12 Month Assessments

First Posted Date: 2012-11-29

Last Posted Date: 2022-07-27

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 289

Registration Number: NCT01736345

Locations: 🇺🇸
The John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States
🇺🇸
The Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy